Cargando…
Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combina...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919124/ https://www.ncbi.nlm.nih.gov/pubmed/33438350 http://dx.doi.org/10.1111/1759-7714.13785 |